Initial target strategies include the monoclonal antibody dupilumab (Dupixent®, Sanofi, Paris, France and Regeneron, NY, USA), that is approved for the treatment as subcutaneous administration of CRSwNP through the pivotal studies LIBERTY NP SINUS (LNPS)-24 and LNPS-52, which has been shown to potently suppress key inflammatory pathways in CRSwNP by inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling [16]. This evidence concerns the gene IL4 and chronic rhinosinusitis with nasal polyps.